Nov 30, 2025, 14:49
Talha Badar ASH25 Key Abstracts to Watch in Acute Lymphoblastic Leukemia
Talha Badar, Hematologist-Oncologist at Mayo Clinic Comprehensive Cancer Center, posted on X:
“ASH25 Key abstracts to watch in acute lymphoblastic leukemia
Overall Takeaways — ASH 2025 ALL Landscape
Rapid movement toward chemo-free or chemo-lite regimens, especially in Ph+ ALL.
TKI + immunotherapy (blina / InO) emerging as new standard-contenders.
CAR-T earlier in therapy (CR1 consolidation and frontline).
Expanding roles for bispecifics and venetoclax-based combinations in R/R ALL.
MRD (especially NGS-MRD) central to future risk-adapted strategies.”
Discover the latest in Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies